Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares

MotleyFool

Mar 18

Brokers have been busy looking over a number of ASX shares this week. Let's see what they are saying about the three named below, which have released updates in recent days. Here's what you need to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2620011984"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620011984\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620011984?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 07:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620011984","market":"nz","top_or_hot":-1,"title":"Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares","media":"MotleyFool","content":"<div>\n<p>Brokers have been busy looking over a number of ASX shares this week.\nLet's see what they are saying about the three named below, which have released updates in recent days. Here's what you need to ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/18/buy-hold-sell-clarity-pharmaceuticals-new-hope-and-orica-shares/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-18 07:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2026/03/18/buy-hold-sell-clarity-pharmaceuticals-new-hope-and-orica-shares/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Brokers have been busy looking over a number of ASX shares this week.\nLet's see what they are saying about the three named below, which have released updates in recent days. Here's what you need to ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/18/buy-hold-sell-clarity-pharmaceuticals-new-hope-and-orica-shares/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7017","symbol_name":"商品化工","start_time":0,"source_url":"https://www.fool.com.au/2026/03/18/buy-hold-sell-clarity-pharmaceuticals-new-hope-and-orica-shares/","article_id":"2620011984","we_media_id":null,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/buy-hold-sell-clarity-pharmaceuticals-new-hope-and-orica-shares/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620011984","pubTimestamp":1773790437,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"Brokers have been busy looking over a number of ASX shares this week.Let's see what they are saying about the three named below, which have released updates in recent days. Here's what you need to know:. As a result, the broker has reaffirmed its speculative buy rating and $6.40 price target on its shares. It said:. The stage is now set for a readout from the approval study for 64Cu-SAR-bisPSMA  which has now ceased accepting new patient consents and is practically fully enrolled . The Co-PSMA data along with data from COBRA and anticipated findings from AMPLIFY will form the basis of submission of a new drug application to be submitted to the FDA.CU6 has three fast track designations for the SAR-bisPSMA agent which includes patients with BCR of prostate cancer following definitive therapy. The company is well funded with cash in excess of $226m at 31 Dec 2025.In light of this, the broker has retained its hold rating with a $5.00 price target. It said:. With leverage to attractive indu","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7017":"商品化工","BK7083":"煤与消费用燃料","CU6.AU":"CLARITY PHARMACEUTICALS LTD","BK7096":"制药","NHC.AU":"NEW HOPE CORP LTD","ORI.AU":"ORICA LTD"},"translate_title":"买入、持有、卖出：Clarity Pharmaceuticals、New Hope和Orica股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NHC.AU":1.5,"CU6.AU":1,"ORI.AU":1.5},"content_text":"Brokers have been busy looking over a number of ASX shares this week.\nLet's see what they are saying about the three named below, which have released updates in recent days. Here's what you need to know:\nClarity Pharmaceuticals Ltd (ASX: CU6)\nBell Potter has been pleased with recent study data relating to this radiopharmaceutical company's 64Cu-SAR-bis-PSMA PET product. It highlights that it is significantly outperforming Ga-PSMA-11 PET in the detection of biochemical recurrence in men with very low PSA levels.\nAs a result, the broker has reaffirmed its speculative buy rating and $6.40 price target on its shares. It said:\nThe stage is now set for a readout from the approval study for 64Cu-SAR-bisPSMA (AMPLIFY) which has now ceased accepting new patient consents and is practically fully enrolled (n=220). The Co-PSMA data along with data from COBRA and anticipated findings from AMPLIFY will form the basis of submission of a new drug application to be submitted to the FDA.\nCU6 has three fast track designations for the SAR-bisPSMA agent which includes patients with BCR of prostate cancer following definitive therapy. The company is well funded with cash in excess of $226m at 31 Dec 2025.\nNew Hope Corporation Ltd (ASX: NHC)\nThis coal miner disappointed analysts at Morgans with its half-year results. The broker highlights that its net profits were much softer than expected.\nIn light of this, the broker has retained its hold rating with a $5.00 price target. It said:\nOverall result missed expectations, with underlying NPAT of A$54m materially below MorgansF (A$63m) and Visible Alpha consensus (A$78m), despite EBITDA of A$215m coming in line with expectations. NHC declared a fully franked 10c dividend, beating MorgansF (8c) and consensus (6c) estimates.\nWith an increasing production profile and material upside potential in coal prices, NHCs outlook remains positive. We maintain a HOLD rating with a target price of A$5.00ps.\nOrica Ltd (ASX: ORI)\nMorgans was pleased with this commercial explosives and blasting systems company's trading update.\nIt was also pleased to see its CF Industries litigation settled and the strengthening of its US operations with an acquisition.\nThis has seen Morgans reiterate its buy rating with an improved price target of $25.35. It said:\nORI's trading update was slightly stronger than we expected. It also announced the settlement of its litigation with CF Industries and the acquisition of its US explosives JV partner, Nelson Brothers, strengthening its US operations. Higher AUD and Indonesia's coal production quotas have seen us make minor revisions to our FY26 forecasts but the acquisition has upgraded FY27/28.\nWith leverage to attractive industry fundamentals, market leading positions, solid earnings growth, proven management team and strong balance sheet, we reiterate our BUY rating with a new price target of A$25.35.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}